Drawing for JUSGARA

USPTO serial 79245746

JUSGARA

Reviewed by CopyMark Law Group

Reg. 5859482Status 404
Filing date
Status date
Registration date
Sep 17, 2019
Examiner
ABRAMS, JACQUELINE WILLETTE
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with JUSGARA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Maury M. Tepper, III

Maury M. Tepper, III Tepper & Eyster, PLLC3724 Benson DriveRaleigh, NC 27609UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastrointestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and the treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthmaSECTION 70 - CANCELLED

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jan 2, 2023DENCNOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED
Jan 2, 2023DETHDEATH OF INTERNATIONAL REGISTRATION
Jan 31, 2020FINVFINAL DECISION TRANSACTION PROCESSED BY IB
Jan 15, 2020FICSFINAL DISPOSITION NOTICE SENT TO IB
Jan 15, 2020FIMPFINAL DISPOSITION PROCESSED
Dec 17, 2019FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Sep 17, 2019R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jul 2, 2019NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 2, 2019PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jun 28, 2019GPNXNOTIFICATION PROCESSED BY IB
Jun 12, 2019OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jun 12, 2019OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jun 12, 2019NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 19, 2019PBCRWITHDRAWN FROM PUB - OG REVIEW QUERY
Feb 2, 2019CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER
Feb 2, 2019RFNTREFUSAL PROCESSED BY IB
Jan 30, 2019TEMETEAS/EMAIL CORRESPONDENCE ENTERED
Jan 30, 2019CRFACORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 28, 2019ALIEASSIGNED TO LIE
Jan 23, 2019TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 16, 2019ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 16, 2019REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jan 12, 2019RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jan 12, 2019RFRRREFUSAL PROCESSED BY MPU
Jan 1, 2019RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Dec 31, 2018CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 31, 2018DOCKASSIGNED TO EXAMINER
Dec 1, 2018MAFRAPPLICATION FILING RECEIPT MAILED
Nov 27, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 26, 2018LIMILIMITATION FROM ORIGINAL APPLICATION ENTERED
Nov 22, 2018REPRSN ASSIGNED FOR SECT 66A APPL FROM IB

Frequently asked questions

Related guidance